Raymond James Initiates Coverage on Liquidia (NASDAQ:LQDA)

Raymond James began coverage on shares of Liquidia (NASDAQ:LQDA) in a report published on Friday morning, Marketbeat.com reports. The brokerage issued an outperform rating and a $27.00 target price on the stock.

A number of other research firms have also weighed in on LQDA. Needham & Company LLC lowered their price objective on Liquidia from $28.00 to $25.00 and set a buy rating on the stock in a research note on Thursday, August 8th. HC Wainwright reissued a buy rating and set a $32.00 price objective on shares of Liquidia in a research note on Wednesday, July 10th. Finally, Oppenheimer assumed coverage on Liquidia in a research note on Tuesday, June 25th. They set a market perform rating on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of Moderate Buy and a consensus price target of $22.43.

Liquidia Price Performance

Shares of NASDAQ:LQDA opened at $9.79 on Friday. The business’s 50 day moving average price is $12.15 and its 200-day moving average price is $13.32. The firm has a market capitalization of $748.09 million, a PE ratio of -6.28 and a beta of 0.32. Liquidia has a 1 year low of $5.71 and a 1 year high of $16.99.

Insider Activity

In other news, CFO Michael Kaseta sold 3,906 shares of the company’s stock in a transaction on Friday, July 12th. The stock was sold at an average price of $12.53, for a total value of $48,942.18. Following the transaction, the chief financial officer now owns 312,389 shares of the company’s stock, valued at approximately $3,914,234.17. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CEO Roger Jeffs sold 8,053 shares of the business’s stock in a transaction on Friday, July 12th. The stock was sold at an average price of $12.53, for a total value of $100,904.09. Following the sale, the chief executive officer now owns 818,932 shares in the company, valued at approximately $10,261,217.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Michael Kaseta sold 3,906 shares of the business’s stock in a transaction on Friday, July 12th. The shares were sold at an average price of $12.53, for a total value of $48,942.18. Following the completion of the sale, the chief financial officer now owns 312,389 shares in the company, valued at approximately $3,914,234.17. The disclosure for this sale can be found here. Insiders have sold a total of 21,437 shares of company stock valued at $268,549 in the last quarter. Insiders own 31.60% of the company’s stock.

Institutional Investors Weigh In On Liquidia

Several institutional investors and hedge funds have recently modified their holdings of the company. Patient Square Capital LP purchased a new stake in shares of Liquidia in the 1st quarter valued at $105,942,000. Vanguard Group Inc. raised its holdings in shares of Liquidia by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 2,887,274 shares of the company’s stock valued at $42,587,000 after buying an additional 43,352 shares during the period. Kynam Capital Management LP raised its holdings in shares of Liquidia by 34.9% in the 4th quarter. Kynam Capital Management LP now owns 2,698,324 shares of the company’s stock valued at $32,461,000 after buying an additional 698,324 shares during the period. Farallon Capital Management LLC purchased a new stake in shares of Liquidia in the 1st quarter valued at $30,311,000. Finally, Vestal Point Capital LP purchased a new stake in shares of Liquidia in the 4th quarter valued at $12,331,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).